Brief: Pharma Mar Announces Its Partner Lotus Pharmaceutical Receives Approval For Zepzelca In Taiwan
11/07/2023 12:26
July 11 (Reuters) - Pharma Mar SA PHMR.MC :
* LOTUS PHARMACEUTICAL RECEIVES ACCELERATED MARKETING
APPROVAL FOR
ZEPZELCA IN TAIWAN
* NEW APPROVAL OF LURBINECTEDIN IS BASED ON DATA FROM
OPEN-LABEL,
MULTICENTER, SINGLE-ARM MONOTHERAPY CLINICAL TRIAL IN 105 ADULT
PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC)
* APPROVAL IS SUBJECT TO CONFIRMATION WITH A PHASE III
CLINICAL
TRIAL
* LURBINECTEDIN IS NOW APPROVED IN 12 COUNTRIES
Source text for Eikon: ID:nCNM9s8JSK
Further company coverage: PHMR.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Lotus Pharmaceutical
See all newsMedia: PTT is said to consider options for Taiwan-listed Lotus Pharma - Bloomberg News
Brief: enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia
Brief: Lotus Pharmaceutical Says Unit Has Closed Deal In Vietnam
Brief: Fuji Pharma: Marketing Approval For Generic Lenalidomide, The First Collaboration Product With Taiwan's Lotus
Brief: Amarin And Lotus Pharmaceuticals Announce Exclusive Partnership In Southeast Asia And South Korea